- Home
- GALT vs SAMG Comparison
GALT vs SAMG Comparison
Compare GALT & SAMG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GALT
- SAMG
- Stock Information
- Founded
- GALT 2000
- SAMG 2002
- Country
- GALT United States
- SAMG United States
- Employees
- GALT N/A
- SAMG N/A
- Industry
- GALT Biotechnology: Pharmaceutical Preparations
- SAMG Investment Managers
- Sector
- GALT Health Care
- SAMG Finance
- Exchange
- GALT Nasdaq
- SAMG Nasdaq
- Market Cap
- GALT 147.8M
- SAMG 171.2M
- IPO Year
- GALT N/A
- SAMG 2013
- Fundamental
- Price
- GALT $2.12
- SAMG $18.33
- Analyst Decision
- GALT Strong Buy
- SAMG
- Analyst Count
- GALT 1
- SAMG 0
- Target Price
- GALT $11.00
- SAMG N/A
- AVG Volume (30 Days)
- GALT 549.5K
- SAMG 21.1K
- Earning Date
- GALT 11-13-2024
- SAMG 10-31-2024
- Dividend Yield
- GALT N/A
- SAMG 4.36%
- EPS Growth
- GALT N/A
- SAMG N/A
- EPS
- GALT N/A
- SAMG 0.79
- Revenue
- GALT N/A
- SAMG $120,231,000.00
- Revenue This Year
- GALT N/A
- SAMG $7.10
- Revenue Next Year
- GALT N/A
- SAMG $5.89
- P/E Ratio
- GALT N/A
- SAMG $23.16
- Revenue Growth
- GALT N/A
- SAMG 2.45
- 52 Week Low
- GALT $1.56
- SAMG $13.93
- 52 Week High
- GALT $4.27
- SAMG $19.20
- Technical
- Relative Strength Index (RSI)
- GALT 39.78
- SAMG 54.12
- Support Level
- GALT $1.80
- SAMG $18.21
- Resistance Level
- GALT $2.36
- SAMG $19.20
- Average True Range (ATR)
- GALT 0.23
- SAMG 0.41
- MACD
- GALT -0.03
- SAMG -0.00
- Stochastic Oscillator
- GALT 26.89
- SAMG 40.41
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About SAMG Silvercrest Asset Management Group Inc.
Silvercrest Asset Management Group Inc is a wealth management firm focused on providing financial advisory and related family office services to ultra-high net-worth individuals and institutional investors. It advises clients on traditional investment strategies focused on equities, fixed income and cash as well as non-traditional investment strategies including hedge funds, private equity funds, real estate and commodities. It also provides clients with family office services and related administrative services, which include financial planning, tax planning and preparation, partnership accounting and fund administration, and consolidated wealth reporting. The company derives revenues principally from assets under management.